| Identification | Back Directory | [Name]
7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamidoxime, 4-amino-7-.beta.-D-ribo furanosyl- | [CAS]
22242-89-3 | [Synonyms]
7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamidoxime, 4-amino-7-.beta.-D-ribo furanosyl-
7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, 4-amino-N-hydroxy-7-β-D-ribofuranosyl- | [Molecular Formula]
C12H16N6O5 | [MOL File]
22242-89-3.mol | [Molecular Weight]
324.29 |
| Chemical Properties | Back Directory | [Boiling point ]
746.5±70.0 °C(Predicted) | [density ]
2.10±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C, protect from light, stored under nitrogen | [solubility ]
DMSO : 170 mg/mL (524.22 mM; Need ultrasonic) | [form ]
Solid | [pka]
6.16±0.69(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors[1]. | [storage]
Store at -20°C, protect from light, stored under nitrogen | [References]
[1]. Dolloff NG, et al. Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther. 2012;11(11):2321-2330. |
|
|